Updated:
Medbio
Medbio was founded in Grand Rapids, Michigan and has grown by acquiring and integrating plastics-focused contract manufacturing operations that serve the...
Medbio
Medbio was founded in Grand Rapids, Michigan and has grown by acquiring and integrating plastics-focused contract manufacturing operations that serve the medical device sector. The firm operates as a holding company that provides injection molding, assembly, and packaging services within certified cleanroom environments. Its customer base is concentrated among large-cap medical device original equipment manufacturers, including firms within the orthopedic, surgical, and specialty instrumentation markets. The strategic mandate centers on acquiring niche injection molders with established customer relationships, then driving organic growth through quality-system alignment and capacity expansion. Medbio's operating companies produce plastic components, subassemblies, and finished single-use devices across categories that include orthopedic implants, surgical robotics consumables, and drug-delivery hardware. The geographic footprint is anchored in the Midwestern United States, with manufacturing facilities clustered in Michigan, a dense corridor for medical device engineering talent and end-market OEM headquarters. Medbio has been backed by private equity firm Graham Partners since at least 2019, with the sponsor targeting add-on acquisitions to deepen capabilities in metal-to-plastic conversion engineering and cleanroom assembly. In December 2024, Medbio acquired Polymer Conversions, a Buffalo-area medical injection molder specializing in complex surgical components, expanding its Northeastern manufacturing presence and adding complementary process expertise (per Plastics News, December 2024). Medbio's architecture is distinct from a conventional manufacturing roll-up because it competes on engineering collaboration with OEM design teams rather than on low-cost unit pricing alone. The firm's governance is sponsor-led, with operational decisions filtered through a portfolio-company board structure rather than a family-office or founder-led model. Succession risk is tied to Graham Partners' hold period rather than generational family transfer.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Grand Rapids
Corporate office
Grand Rapids, MI, United States
Sector focus
Frequently asked questions
What does Medbio actually manufacture?
Medbio's operating companies injection-mold plastic components, subassemblies, and single-use consumables for medical device OEMs. The firm specializes in cleanroom production of parts that go into orthopedic implants, surgical robotics instruments, and drug-delivery devices. Medbio does not design or own the finished devices — it builds to customer specifications under quality-system certification.
Who owns Medbio?
Medbio has been a portfolio company of Graham Partners, a Philadelphia-based private equity firm, since at least 2019. Graham Partners focuses on advanced manufacturing and industrial technology investments. Medbio operates as a platform that acquires additional injection-molding businesses to integrate into its network.
Which medical device OEMs does Medbio supply?
Medbio has publicly cited relationships with large-cap orthopedic and surgical device manufacturers headquartered in the Midwest. Stryker, the Kalamazoo-based orthopedics and robotics giant, and Zimmer Biomet, the Warsaw, Indiana implant maker, represent the type and geography of OEM customer that sits in Medbio's core supply chain (per industry concentration patterns and Medbio's stated location strategy).
How does Medbio grow — organically or through acquisition?
Medbio uses a hybrid model: it acquires niche medical injection molders with established OEM contracts, then invests in capacity expansion and quality-system maturation to deepen those relationships. This buy-and-build approach under Graham Partners has added facilities across Michigan and New York, including the December 2024 acquisition of Polymer Conversions, which brought metal-to-plastic conversion expertise into the platform.
What regulatory certifications do Medbio's facilities hold?
Medbio's plants operate certified cleanrooms that comply with ISO 13485, the quality-management standard specific to medical device manufacturing, and are FDA-registered establishments. The firm's customer base requires production within these frameworks as a condition of supplier qualification.
Is Medbio a single-family office?
No. Medbio is a contract manufacturing platform company backed by institutional private equity. It does not manage family capital, make passive investments, or operate a direct-investment portfolio. The name reflects its medical-bio manufacturing focus, not a family office structure.
How does Medbio's acquisition strategy affect its supplier relationships?
Each acquired facility generally retains its legacy customer contracts and engineering teams. Medbio's value-add is centralized quality-system investment and cross-site capacity coordination. OEMs operating across multiple Medbio sites can access expanded production scale without switching suppliers, which the firm presents as supply-chain continuity rather than vendor consolidation.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: